|View printer-friendly version|
"At Accuray, more than 50 percent of the U.S. Field
According to a 2012 U.S. Veterans Affairs (VA) study of VA cancer patients, 97.5% of whom were male, the five most frequently diagnosed cancers were prostate, lung and bronchial, colorectal, urinary and bladder cancers, and skin melanomas. While this mirrors the most commonly diagnosed cancers in the general population of American men, veterans are at higher risk for developing these cancers, which are often effectively treated using targeted radiation therapy.
Through the VA Choice Program, established as part of the Veterans Access, Choice, and Accountability Act of 2014 (VACAA), veterans enrolled in VA health can receive care within their community or see a cancer specialist with the most advanced technology, such as the
"As a veteran, I'm proud that
Important Safety Information
For Important Safety Information please refer to http://www.accuray.com/safety-statement
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical results, our ability to provide veterans with access to our technology, and
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Public Relations Director,
+1 (408) 789-4426
+1 (781) 684-0770
View original content with multimedia:http://www.prnewswire.com/news-releases/accuray-military-veterans-support-us-veteran-community-300551578.html
© 2007 - 2016 Accuray Incorporated. All Rights Reserved. Accuray, the stylized logo, CyberKnife, TomoTherapy, Synchrony, Xsight, Xchange, TomoHD, Hi-Art, and RoboCouch are among the trademarks and / or registered trademarks of Accuray Incorporated in the United States and other countries.
Important Safety Information: Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death.
Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.